1
|
Simpson EL, Schlievert PM, Yoshida T, Lussier S, Boguniewicz M, Hata T, Fuxench Z, De Benedetto A, Ong PY, Ko J, Calatroni A, Rudman Spergel AK, Plaut M, Quataert SA, Kilgore SH, Peterson L, Gill AL, David G, Mosmann T, Gill SR, Leung DYM, Beck LA. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol 2023; 152:1179-1195. [PMID: 37315812 PMCID: PMC10716365 DOI: 10.1016/j.jaci.2023.05.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2022] [Revised: 05/05/2023] [Accepted: 05/11/2023] [Indexed: 06/16/2023]
Abstract
BACKGROUND Atopic dermatitis (AD) is an inflammatory disorder characterized by dominant type 2 inflammation leading to chronic pruritic skin lesions, allergic comorbidities, and Staphylococcus aureus skin colonization and infections. S aureus is thought to play a role in AD severity. OBJECTIVES This study characterized the changes in the host-microbial interface in subjects with AD following type 2 blockade with dupilumab. METHODS Participants (n = 71) with moderate-severe AD were enrolled in a randomized (dupilumab vs placebo; 2:1), double-blind study at Atopic Dermatitis Research Network centers. Bioassays were performed at multiple time points: S aureus and virulence factor quantification, 16s ribosomal RNA microbiome, serum biomarkers, skin transcriptomic analyses, and peripheral blood T-cell phenotyping. RESULTS At baseline, 100% of participants were S aureus colonized on the skin surface. Dupilumab treatment resulted in significant reductions in S aureus after only 3 days (compared to placebo), which was 11 days before clinical improvement. Participants with the greatest S aureus reductions had the best clinical outcomes, and these reductions correlated with reductions in serum CCL17 and disease severity. Reductions (10-fold) in S aureus cytotoxins (day 7), perturbations in TH17-cell subsets (day 14), and increased expression of genes relevant for IL-17, neutrophil, and complement pathways (day 7) were also observed. CONCLUSIONS Blockade of IL-4 and IL-13 signaling, very rapidly (day 3) reduces S aureus abundance in subjects with AD, and this reduction correlates with reductions in the type 2 biomarker, CCL17, and measures of AD severity (excluding itch). Immunoprofiling and/or transcriptomics suggest a role for TH17 cells, neutrophils, and complement activation as potential mechanisms to explain these findings.
Collapse
Affiliation(s)
- Eric L Simpson
- Department of Dermatology, Oregon Health and Science University, Portland, Ore
| | | | - Takeshi Yoshida
- Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY
| | | | - Mark Boguniewicz
- Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo
| | - Tissa Hata
- Department of Dermatology, University of California, San Diego, Calif
| | - Zelma Fuxench
- Department of Dermatology, University of Pennsylvania, Philadelphia, Pa
| | - Anna De Benedetto
- Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY
| | - Peck Y Ong
- Department of Pediatrics, University Southern California, Los Angeles, Calif
| | - Justin Ko
- Department of Dermatology, Stanford University, Stanford, Calif
| | | | - Amanda K Rudman Spergel
- Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Marshall Plaut
- Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| | - Sally A Quataert
- Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, NY
| | - Samuel H Kilgore
- Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa
| | - Liam Peterson
- Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY
| | - Ann L Gill
- Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY
| | | | - Tim Mosmann
- Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, NY
| | - Steven R Gill
- Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY
| | - Donald Y M Leung
- Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colo.
| | - Lisa A Beck
- Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, NY.
| |
Collapse
|
2
|
Jhaveri K, Eli LD, Wildiers H, Hurvitz SA, Guerrero-Zotano A, Unni N, Brufsky A, Park H, Waisman J, Yang ES, Spanggaard I, Reid S, Burkard ME, Vinayak S, Prat A, Arnedos M, Bidard FC, Loi S, Crown J, Bhave M, Piha-Paul SA, Suga JM, Chia S, Saura C, Garcia-Saenz JÁ, Gambardella V, de Miguel MJ, Gal-Yam EN, Rapael A, Stemmer SM, Ma C, Hanker AB, Ye D, Goldman JW, Bose R, Peterson L, Bell JSK, Frazier A, DiPrimeo D, Wong A, Arteaga CL, Solit DB. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023; 34:885-898. [PMID: 37597578 DOI: 10.1016/j.annonc.2023.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 08/03/2023] [Accepted: 08/08/2023] [Indexed: 08/21/2023] Open
Abstract
BACKGROUND HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (seven in each arm) from a randomized substudy of fulvestrant versus fulvestrant + trastuzumab (F + T) versus N + F + T. PATIENTS AND METHODS Patients with HR+ HER2-negative MBC with activating HER2 mutation(s) and prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy received N + F + T (oral neratinib 240 mg/day with loperamide prophylaxis, intramuscular fulvestrant 500 mg on days 1, 15, and 29 of cycle 1 then q4w, intravenous trastuzumab 8 mg/kg then 6 mg/kg q3w) or F + T or fulvestrant alone. Those whose disease progressed on F + T or fulvestrant could cross-over to N + F + T. Efficacy endpoints included investigator-assessed objective response rate (ORR), clinical benefit rate (RECIST v1.1), duration of response, and progression-free survival (PFS). Plasma and/or formalin-fixed paraffin-embedded tissue samples were collected at baseline; plasma was collected during and at end of treatment. Extracted DNA was analyzed by next-generation sequencing. RESULTS ORR for 57 N + F + T-treated patients was 39% [95% confidence interval (CI) 26% to 52%); median PFS was 8.3 months (95% CI 6.0-15.1 months). No responses occurred in fulvestrant- or F + T-treated patients; responses in patients crossing over to N + F + T supported the requirement for neratinib in the triplet. Responses were observed in patients with ductal and lobular histology, 1 or ≥1 HER2 mutations, and co-occurring HER3 mutations. Longitudinal circulating tumor DNA sequencing revealed acquisition of additional HER2 alterations, and mutations in genes including PIK3CA, enabling further precision targeting and possible re-response. CONCLUSIONS The benefit of N + F + T for HR+ HER2-mutant MBC after progression on CDK4/6is is clinically meaningful and, based on this study, N + F + T has been included in the National Comprehensive Cancer Network treatment guidelines. SUMMIT has improved our understanding of the translational implications of targeting HER2 mutations with neratinib-based therapy.
Collapse
Affiliation(s)
- K Jhaveri
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York.
| | - L D Eli
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - H Wildiers
- University Hospitals Leuven, Leuven, Belgium
| | - S A Hurvitz
- David Geffen School of Medicine, UCLA, Los Angeles, Santa Monica, USA
| | - A Guerrero-Zotano
- Medical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain
| | - N Unni
- UT Southwestern Medical Center, Dallas
| | - A Brufsky
- Magee-Womens Hospital of UPMC, Pittsburgh
| | - H Park
- Washington University School of Medicine, St. Louis
| | - J Waisman
- City of Hope Comprehensive Cancer Center, Duarte
| | - E S Yang
- University of Alabama at Birmingham, Birmingham, USA
| | - I Spanggaard
- Department of Oncology, Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - S Reid
- Division of Hematology/Oncology (Breast Oncology), The Vanderbilt-Ingram Cancer Center, Nashville
| | - M E Burkard
- Division of Hematology/Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison
| | - S Vinayak
- Seattle Cancer Care Alliance, Seattle, USA
| | - A Prat
- Hospital Clínic de Barcelona, Barcelona, Spain
| | - M Arnedos
- Department of Medical Oncology, Gustave Roussy, Villejuif
| | - F-C Bidard
- Department of Medical Oncology, UVSQ/Paris-Saclay University, Institut Curie, Saint Cloud, France
| | - S Loi
- Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne; The Sir Peter MacCallum Department of Medical Oncology, The University of Melbourne, Parkville, Australia
| | - J Crown
- St. Vincent's University Hospital, Dublin, Ireland
| | - M Bhave
- Department of Hematology/Oncology, Emory University, Winship Cancer Institute, Atlanta
| | - S A Piha-Paul
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston
| | - J M Suga
- Kaiser Permanente, Department of Medical Oncology, Vallejo, USA
| | - S Chia
- Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - C Saura
- Medical Oncology Service, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - J Á Garcia-Saenz
- Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid
| | - V Gambardella
- Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia
| | - M J de Miguel
- START Madrid - Hospital Universitario Madrid Sanchinarro, Madrid, Spain
| | - E N Gal-Yam
- Institute of Breast Oncology, Sheba Medical Center, Ramat Gan
| | - A Rapael
- Sourasky Medical Center, Tel Aviv
| | - S M Stemmer
- Davidoff Cancer Center, Rabin Medical Center, Petah Tikva; Tel Aviv University, Tel Aviv, Israel
| | - C Ma
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | - A B Hanker
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | - D Ye
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | | | - R Bose
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | - L Peterson
- Division of Medical Oncology, Department of Medicine and Siteman Cancer Center, Washington University, St. Louis
| | | | - A Frazier
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - D DiPrimeo
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - A Wong
- Clinical Development, Puma Biotechnology, Los Angeles, USA
| | - C L Arteaga
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas
| | - D B Solit
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
| |
Collapse
|
3
|
Davis A, Luo J, Zheng T, Dai C, Suresh R, Ademuyiwa F, Rigden C, Clifton K, Weilbaecher K, Frith A, Tandra P, Summa T, Thomas S, Peterson L, Wang X, Du P, Jia S, King B, Krishnamurthy J, Ma C. 108P Copy loss enrichment at metastatic disease progression in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibition. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Janssen M, Peters M, Steijvers-Peeters E, Szomolanyi P, Jutten E, van Rhijn L, Peterson L, Lindahl A, Trattnig S, Emans P. 7-Tesla MRI Evaluation of the Knee, 25 Years after Cartilage Repair Surgery: The Influence of Intralesional Osteophytes on Biochemical Quality of Cartilage. Cartilage 2021; 13:767S-779S. [PMID: 34836478 PMCID: PMC8808805 DOI: 10.1177/19476035211060506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
OBJECTIVE To evaluate the morphological and biochemical quality of cartilage transplants and surrounding articular cartilage of patients 25 years after perichondrium transplantation (PT) and autologous chondrocyte transplantation (ACT) as measured by ultra-high-field 7-Tesla (7T) magnetic resonance imaging (MRI) and to present these findings next to clinical outcome. DESIGN Seven PT patients and 5 ACT patients who underwent surgery on the femoral condyle between 1986 and 1996 were included. Patient-reported outcome measures (PROMs) were assessed by the clinical questionnaires: Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC), and Visual Analogue Scale (VAS) for knee pain. The morphological (MOCART score) and biochemical quality (glycosaminoglycans [GAGs] content and collagen integrity) of cartilage transplants and surrounding articular cartilage were analyzed by 7T MRI. The results of the PT and ACT patients were compared. Finally, a detailed morphological analysis of the grafts alone was performed. RESULTS No statistically significant difference was found for the PROMs and MOCART scores of PT and ACT patients. Evaluation of the graft alone showed poor repair tissue quality and high prevalence of intralesional osteophyte formation in both the PT and ACT patients. Penetration of the graft surface by the intralesional osteophyte was related to biochemically damaged opposing tibial cartilage; GAG content was significantly lower in patients with an osteophyte penetrating the graft surface. CONCLUSIONS Both PT and ACT patients have a high incidence of intralesional osteophyte formation 25 years after surgery. The resulting biochemical damage to the opposing tibial cartilage might be dependent on osteophyte morphology.
Collapse
Affiliation(s)
- M.P.F. Janssen
- Department of Orthopaedic Surgery,
CAPHRI School for Public Health and Primary Care, Maastricht University Medical
Center+, Maastricht, The Netherlands,M.P.F. Janssen, Department of Orthopaedic
Surgery, CAPHRI School for Public Health and Primary Care, Maastricht University
Medical Center+, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
| | - M.J.M. Peters
- Department of Orthopaedic Surgery,
CAPHRI School for Public Health and Primary Care, Maastricht University Medical
Center+, Maastricht, The Netherlands
| | | | - P. Szomolanyi
- High-Field MR Center, Department of
Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna,
Austria
| | - E.M.C. Jutten
- Department of Orthopaedic Surgery,
CAPHRI School for Public Health and Primary Care, Maastricht University Medical
Center+, Maastricht, The Netherlands
| | - L.W. van Rhijn
- Department of Orthopaedic Surgery,
CAPHRI School for Public Health and Primary Care, Maastricht University Medical
Center+, Maastricht, The Netherlands
| | - L. Peterson
- Department of Laboratory Medicine,
Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg,
Sweden
| | - A. Lindahl
- Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden
| | - S. Trattnig
- High-Field MR Center, Department of
Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna,
Austria
| | - P.J. Emans
- Department of Orthopaedic Surgery,
CAPHRI School for Public Health and Primary Care, Maastricht University Medical
Center+, Maastricht, The Netherlands
| |
Collapse
|
5
|
Gordon K, Foley P, Krueger JG, Pinter A, Reich K, Vender R, Vanvoorden V, Madden C, Peterson L, Blauvelt A. Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal. ACTA ACUST UNITED AC 2020. [DOI: 10.25251/skin.4.supp.83] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abstract not available.
Collapse
|
6
|
Betz M, Steenes A, Peterson L, Saunders M. Knowledge of Sodium, Potassium & Phosphorus in Patients with Non-Dialysis Dependent Chronic Kidney Disease Stages 3b-5. J Acad Nutr Diet 2019. [DOI: 10.1016/j.jand.2019.08.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Augustin M, Wegtowska J, Lebwohl M, Paul C, Piguet V, Sofen H, Blauvelt A, Peterson L, Arendt C, Rolleri R. Clinical Response in Plaque Psoriasis Patients Switching from Etanercept to Certolizumab Pegol in a Phase 3, Randomized, Controlled Study. ACTA ACUST UNITED AC 2018. [DOI: 10.25251/skin.2.supp.87] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abstract not available. Disclosures: Study sponsored by Dermira. Copyright 2018 SKIN
Collapse
|
8
|
Augustin M, Wegtowska J, Lebwohl M, Paul C, Piguet V, Sofen H, Blauvelt A, Peterson L, Al. E. Durability of Response in Patients with Chronic Plaque Psoriasis Treated with Certolizumab Pegol over 48 Weeks: Pooled Results from Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1, CIMPASI-2 and CIMPACT). ACTA ACUST UNITED AC 2018. [DOI: 10.25251/skin.2.supp.88] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Abstract not available. Disclosures: Study sponsored by Dermira.Copyright 2018 SKIN
Collapse
|
9
|
Hegazy S, Augustin M, Węgłowska J, Lebwohl M, Piguet V, Sofen H, Blauvelt A, Peterson L, Arendt C, Rolleri R. Efficacité du certolizumab pégol chez des patients souffrant de psoriasis ne répondant pas à l’étanercept : résultats d’une étude contrôlée randomisée de phase III en cours. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Dobbs D, Peterson L, Sardina A, Tan S, Brown-Hughes T, Sadeq N, Andel R, Gamaldo A. OLDER BLACKS’ EXPERIENCES WITH TRADITIONAL PAPER-AND-PENCIL VERSUS COMPUTERIZED COGNITIVE BATTERIES. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | - A Sardina
- University of North Carolina Wilmington
| | - S Tan
- Pennsylvania State University
| | | | | | - R Andel
- University of South Florida, School of Aging Studies
| | | |
Collapse
|
11
|
Hyer K, Dosa D, Peterson L, June J, Jester D, Dobbs D, Thomas K. DILEMMAS FACING NURSING HOMES AND ASSISTED LIVING PROVIDERS DURING HURRICANES. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- K Hyer
- University of South Florida, Tampa, Florida, United States
| | - D Dosa
- Brown University, Box G-S121 (6); 121 South Main Street; Providence VA, Providence, RI
| | - L Peterson
- Florida Policy Exchange Center on Aging, University of South Florida, Tampa
| | - J June
- University of South Florida, Tampa, FL
| | - D Jester
- University of South Florida, Tampa
| | - D Dobbs
- Florida Policy Exchange Center on Aging, University of South Florida, Tampa, FL
| | - K Thomas
- Brown University, Providence, RI; Providence VA, Providence, RI
| |
Collapse
|
12
|
June J, Peterson L, Dosa D, Thomas K, Li M, Sun X, Sakib N, Hyer K. IMPACT OF HURRICANE IRMA ON EVACUATION PREPAREDNESS AND RESPONSE OF FLORIDA ASSISTED LIVING COMMUNITIES. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- J June
- University of South Florida
| | | | | | | | - M Li
- University of South Florida
| | - X Sun
- Department of Industrial & Management Systems Engineering, University of South Florida
| | - N Sakib
- Department of Industrial & Management Systems Engineering, University of South Florida
| | - K Hyer
- University of South Florida
| |
Collapse
|
13
|
Blauvelt A, Reich K, Lebwohl M, Burge D, Arendt C, Peterson L, Drew J, Rolleri R, Gottlieb AB. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. J Eur Acad Dermatol Venereol 2018; 33:546-552. [PMID: 30242918 PMCID: PMC6646900 DOI: 10.1111/jdv.15258] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2018] [Accepted: 08/29/2018] [Indexed: 11/28/2022]
Abstract
BACKGROUND Certolizumab pegol, an Fc-free, PEGylated, anti-tumour necrosis factor (TNF) biologic, has demonstrated favourable results in three ongoing, phase 3, randomized, double-blinded, placebo-controlled trials in adults with psoriasis. OBJECTIVE Data were pooled from the ongoing trials to investigate efficacy in selected subgroups and add precision to estimates of treatment effects during the initial 16 weeks of treatment. METHODS In each trial, patients ≥18 years with moderate-to-severe chronic plaque psoriasis for ≥6 months were randomized to receive certolizumab 400 mg, certolizumab 200 mg or placebo every 2 weeks for 16 weeks. Coprimary endpoints for the pooled analysis were responder rates at Week 16, defined as ≥75% reduction in psoriasis area and severity index (PASI 75) and physician global assessment (PGA) of 0/1 ('clear'/'almost clear' with ≥2-category improvement). Safety was assessed by treatment-emergent adverse events. RESULTS A total of 850 patients treated with certolizumab 400 mg (N = 342), certolizumab 200 mg (N = 351) or placebo (N = 157) were included in the pooled analysis. At Week 16, PASI 75 and PGA 0/1 responder rates were 80.1% and 63.7% in the certolizumab 400 mg group, 74.5% and 54.6% in the certolizumab 200 mg group, and 7.5% and 2.8% in the placebo group (P < 0.0001 for each dose versus placebo). In patients with and without prior biologic therapy, both doses of certolizumab resulted in substantially higher responder rates versus placebo. The incidence of adverse events was generally similar between the 400 mg and placebo groups, and somewhat lower in the 200 mg group versus placebo. No new safety signals were identified. CONCLUSION Certolizumab pegol 400 mg or 200 mg every 2 weeks for 16 weeks was associated with statistically significant and clinically meaningful improvements in signs and symptoms of psoriasis in patients with and without prior biologic therapy, and a safety profile consistent with the anti-TNF class in psoriasis.
Collapse
Affiliation(s)
- A Blauvelt
- Oregon Medical Research Center, Portland, OR, USA
| | - K Reich
- Dermatologikum Berlin and SCIderm Research Institute, Hamburg, Germany
| | - M Lebwohl
- Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - D Burge
- Dermira, Inc., Menlo Park, CA, USA
| | | | | | - J Drew
- Dermira, Inc., Menlo Park, CA, USA
| | | | - A B Gottlieb
- New York Medical College at Metropolitan Hospital, New York, NY, USA
| |
Collapse
|
14
|
Lebwohl M, Paul C, Sofen H, Węgłowska J, Augstin M, Piguet V, Drew J, Burge D, Peterson L, Rolleri B, Blauvelt A. Traitement du psoriasis par certolizumab pégol : résultats de l’étude de phase 3 CIMPACT, multicentrique, randomisée, contrôlée vs. étanercept et vs. placebo. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Vandame D, Gottlieb A, Blauvelt A, Leonardi C, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Traitement du psoriasis par certolizumab pegol : résultats des études de phase 3 CIMPASI 1&2, multicentriques, randomisées et contrôlées vs. PBO. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
16
|
Corrigan C, Peterson L, McVeigh C, Lavin PJ, Mellotte GJ, Wall C, Baker Kerrigan A, Barnes L, O'Neill D, Moss H. The Perception of Art among Patients and Staff on a Renal Dialysis Unit. Ir Med J 2017; 110:632. [PMID: 29372947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
This study investigated the purpose and effectiveness of giving outpatients an opportunity to engage in art activities while receiving dialysis treatment. A mixed method study was conducted. 21 semi-structured interviews were conducted with outpatients attending the dialysis unit and 13 surveys of clinicians were completed. The principle reasons to partake in the art activity programme included: to pass time, to relieve boredom, to be creative, to try something new, distraction from concerns, to stay positive and to achieve something new. Patients who did not participate in the programme pass their time primarily by watching TV or sleeping. All staff who partook in the survey were satisfied with the programme and wanted it to continue. Our findings indicate that the creative arts programme is viewed positively by staff and patients alike, and might be useful in other hospital departments. Further in depth qualitative research would be useful to interrogate the potential effect of engagement in art on positive mental health and quality of life for patients with chronic conditions.
Collapse
Affiliation(s)
- C Corrigan
- Trinity College Dublin School of Medicine
| | - L Peterson
- Trinity College Dublin School of Medicine
| | - C McVeigh
- Trinity College Dublin School of Medicine
| | - P J Lavin
- Trinity Health Kidney Centre, Tallaght Hospital, Dublin 24
| | - G J Mellotte
- Trinity Health Kidney Centre, Tallaght Hospital, Dublin 24
| | - C Wall
- Trinity Health Kidney Centre, Tallaght Hospital, Dublin 24
| | - A Baker Kerrigan
- National Centre for Arts and Health Tallaght Hospital, Dublin 24
| | - L Barnes
- National Centre for Arts and Health Tallaght Hospital, Dublin 24
| | - D O'Neill
- Trinity College Dublin School of Medical Gerontology
| | | |
Collapse
|
17
|
Rabin P, Houg S, Lapin B, Schora D, Peterson L, Donlan S. 257 The Medical Coat: Bacterial Vector Versus Professional Traditional. Ann Emerg Med 2016. [DOI: 10.1016/j.annemergmed.2016.08.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
18
|
Abstract
The frequency of spondylolysis and the relationship between spondylolysis and the sacro-horizontal angle in 143 athletes and 30 non-athletes is reported. Athletes had a larger sacro-horizontal angle than non-athletes. The sacro-horizontal angle was larger in athletes with spondylolysis as compared with those without. An increased incidence of spondylolysis with an increased angle was demonstrated. It is suggested that an increased sacro-horizontal angle may predispose to spondylolysis, especially in combination with the high mechanical loads sustained in certain sports.
Collapse
|
19
|
Abstract
A radiologic study of the thoraco-lumbar spine was performed in 143 (117 male and 26 female) athletes (wrestlers, gymnasts, soccer players and tennis players), aged 14 to 25 years and 30 male non-athletes, aged 19 to 25 years. Film interpretation was made after mixing the films from all groups and without knowledge of the individual's identity. Various types of radiologic abnormalities occurred in both athletes and non-athletes but were more common among athletes, especially male gymnasts and wrestlers. Abnormalities of the vertebral ring apophysis occurred exclusively in athletes. Combinations of different types of abnormalities were most common in male gymnasts and wrestlers.
Collapse
|
20
|
Kälebo P, Goksör LÅ, Swärd L, Peterson L. Soft-Tissue Radiography, Computed Tomography, and Ultrasonography of Partial Achilles Tendon Ruptures. Acta Radiol 2016. [DOI: 10.1177/028418519003100606] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Ultrasonography (US) was compared with soft-tissue radiography (STR) and computed tomography (CT) for demonstration of partial Achilles tendon ruptures. Thirty-nine patients suffering from chronic localized painful Achilles tendon swelling were examined. The patients had all undergone a previous clinical examination, resulting in a suspicion of a non-healed partial tear in 62 out of the 78 tendons. STR showed unspecific tendon pathology such as thickening and diffuse tendon margins. CT resulted in a better delineation of intra- as well as extratendinous abnormalities compared to STR. Various pathologic changes were seen on CT in 54 tendons and in 29 of these, localized intratendinous hypodensities indicated partial ruptures. At US, abnormal changes were observed in 69 tendons, of which 54 had discontinuity of tendon fibers, focal hypoechoic areas, and localized swelling indicating partial ruptures. In 9 cases with surgically proven partial ruptures, US was correct in all cases, while CT was false-negative in 3. STR only showed localized swelling. It was concluded that US was a better method than STR and CT for the detection of partial ruptures and the US findings correlated well with the surgical findings.
Collapse
|
21
|
|
22
|
van der Heijde D, Dougados M, Landewé R, Sieper J, Maksymowych W, Rudwaleit M, van den Bosch F, Braun J, Mease P, Davies O, Hoepken B, Peterson L, Deodhar A. SAT0375 Certolizumab Pegol for The Treatment of Axial Spondyloarthritis: 4-Year Outcomes from The Rapid-AXSPA Trial. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3142] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
23
|
Mease P, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, Peterson L, van der Heijde D. FRI0472 Improvements in Joint Outcomes of Psoriatic Arthritis over 4 Years of Treatment with Certolizumab Pegol in Patients with and without Prior Anti-TNF Exposure. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
24
|
Mease P, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, Peterson L, van der Heijde D. FRI0471 Certolizumab Pegol for The Treatment of Psoriatic Arthritis: 4-Year Outcomes from The Rapid-Psa Trial. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.3192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Specht JM, Partridge S, Chai X, Novakova A, Peterson L, Shields A, Guenthoer J, Linden HM, Gralow JR, Gadi V, Korde L, Hills D, Hsu L, Hockenbery DM, Kinahan P, Mankoff DA, Porter PL. Abstract P5-01-02: Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-01-02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Using quantitative FDG PET to measure glucose metabolism and perfusion, and dynamic contrast-enhanced (DCE) MRI to measure perfusion, we previously identified a metabolic signature for breast cancer resistant to NAC. This imaging signature is (1) persistent or increased tumor perfusion despite treatment, (2) an altered pattern of glucose kinetics in response to therapy, and (3) pre-therapy mismatch between tumor metabolism (MRFDG) and glucose delivery (K1) (high ratio of MRFDG/K1). These patterns predict poor response, early relapse and death independent of established prognostic factors, including pathologic response. Identification of factors associated with resistance or response to therapy is the translational goal of "Quantitative Dynamic PET and MRI in Breast Cancer Therapy," part of the Seattle Breast SPORE (1P50CA138293).
Methods: Patients (Pts) undergoing NAC for histologically confirmed breast cancer (stage II-III) were approached for this trial (CCIRB# 7587). FDG PET and DCE-MRI were obtained pre-therapy, 2-12 weeks after start of NAC (mid-therapy) and after completion of NAC. Breast biopsies were obtained pre-therapy and post-NAC. FDG PET included a dynamic scan with kinetic analysis. PET measures included SUVmax, MRFDG, K1, Ki, and Patlak. 3T DCE-MRI measurements included semi-quantitative vascular parameters of peak enhancement (PE), signal enhancement ratio (SER), washout fraction, functional tumor volume, and apparent diffusion coefficient (ADC) from diffusion-weighted MRI (DWI). Breast biopsies were assayed by immunohistochemistry and gene expression profiling. NAC was per physician's choice with most pts receiving weekly paclitaxel (with trastuzumab if HER2+) followed by doxorubicin/cyclophosphamide.
Results: 32 pts have completed the study. Pathologic complete response (pCR), defined as absence of invasive cancer in the breast, was observed in 9 (28%); near pCR defined as only microscopic residual invasive cancer in 3 (9%) more pts. Mid-therapy decline in SUVmax and K1 was associated with near pCR; (p-value 0.06, 0.04, respectively). Pre-therapy PET measures of MRFDG and K1 were not predictive of pCR. On MRI, pre-therapy PE (p=0.009), SER (p=0.01), washout fraction (p=0.02), ADC (p=0.08, trend) and mid-therapy change in volume (p=0.05) were each predictive of pCR. Gene profiling of pre-therapy biopsies showed correlation between high MRFDG/K1 ratio in basal and luminal B tumors.
Conclusions: Assessment of serial changes in tumor metabolism and perfusion by FDG PET and DCE-MRI is feasible in the clinic. Mid-therapy decline in metabolism and glucose delivery was predictive of pCR; consistent with prior retrospective series. Baseline DCE-MRI and DWI measures show promise to predict response, and associations of mid-therapy change in MR functional tumor volume with pCR agree with findings of another multisite clinical trial (ISPY). These imaging parameters may serve as useful biomarkers to inform future neoadjuvant trials. Integration of imaging data with gene expression profiling revealed that the pattern of metabolism in luminal B tumors was closer to that of the basal subtype compared to other ER-positive tumors.
Citation Format: Specht JM, Partridge S, Chai X, Novakova A, Peterson L, Shields A, Guenthoer J, Linden HM, Gralow JR, Gadi V, Korde L, Hills D, Hsu L, Hockenbery DM, Kinahan P, Mankoff DA, Porter PL. Multimodality molecular imaging with dynamic 18F-fluorodeoxyglucose positron emission tomography (FDG PET) and MRI to evaluate response and resistance to neoadjuvant chemotherapy (NAC). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-01-02.
Collapse
Affiliation(s)
- JM Specht
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - S Partridge
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - X Chai
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - A Novakova
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - L Peterson
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - A Shields
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - J Guenthoer
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - HM Linden
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - JR Gralow
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - V Gadi
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - L Korde
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - D Hills
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - L Hsu
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - DM Hockenbery
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - P Kinahan
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - DA Mankoff
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| | - PL Porter
- University of Washington, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; Bassett Cancer Institute, Cooperstown, NY; University of Pennsylvania, Philadelphia, PA
| |
Collapse
|
26
|
Lee CJ, Brown TT, Cheskin LJ, Choi P, Moran TH, Peterson L, Matuk R, Steele KE. Effects of meal composition on postprandial incretin, glucose and insulin responses after surgical and medical weight loss. Obes Sci Pract 2015; 1:104-109. [PMID: 27774253 PMCID: PMC5064622 DOI: 10.1002/osp4.17] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 10/26/2015] [Accepted: 11/03/2015] [Indexed: 12/13/2022] Open
Abstract
Background Meal tolerance tests are frequently used to study dynamic incretin and insulin responses in the postprandial state; however, the optimal meal that is best tolerated and suited for hormonal response following surgical and medical weight loss has yet to be determined. Objective To evaluate the tolerability and effectiveness of different test meals in inducing detectable changes in markers of glucose metabolism in individuals who have undergone a weight loss intervention. Methods Six individuals who underwent surgical or medical weight loss (two Roux‐en‐Y gastric bypass, two sleeve gastrectomy and two medical weight loss) each completed three meal tolerance tests using liquid‐mixed, solid‐mixed and high‐fat test meals. The tolerability of each test meal, as determined by the total amount consumed and palatability, as well as fasting and meal‐stimulated glucagon‐like peptide, glucose‐dependent insulinotropic polypeptide, insulin and glucose were measured. Results Among the six individuals, the liquid‐mixed meal was better and more uniformly tolerated with a median meal completion rate of 99%. Among the four bariatric surgical patients, liquid‐mixed meal stimulated on average a higher glucagon‐like peptide (percent difference: 83.7, 89), insulin secretion (percent difference: 155.1, 158.7) and glucose‐dependent insulinotropic polypeptide (percent difference: 113.5, 34.3) compared with solid‐mixed and high‐fat meals. Conclusions The liquid‐mixed meal was better tolerated with higher incretin and insulin response compared with the high‐fat and solid‐mixed meals and is best suited for the evaluation of stimulated glucose homeostasis.
Collapse
Affiliation(s)
- C J Lee
- Division of Endocrinology, Diabetes and Metabolism The Johns Hopkins University Baltimore Maryland USA
| | - T T Brown
- Division of Endocrinology, Diabetes and Metabolism The Johns Hopkins University Baltimore Maryland USA
| | - L J Cheskin
- Department of Health, Behavior and Society The Johns Hopkins Bloomberg School of Public Health Baltimore Maryland USA
| | - P Choi
- Department of Psychiatry The Johns Hopkins University Baltimore Maryland USA
| | - T H Moran
- Department of Psychiatry The Johns Hopkins University Baltimore Maryland USA
| | - L Peterson
- Department of Surgery The Johns Hopkins University Baltimore Maryland USA
| | - R Matuk
- Department of Surgery The Johns Hopkins University Baltimore Maryland USA
| | - K E Steele
- Department of Surgery The Johns Hopkins University Baltimore Maryland USA
| |
Collapse
|
27
|
Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D. Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure. RMD Open 2015; 1:e000119. [PMID: 26509074 PMCID: PMC4612702 DOI: 10.1136/rmdopen-2015-000119] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 06/01/2015] [Accepted: 06/07/2015] [Indexed: 12/16/2022] Open
Abstract
Objective Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with psoriatic arthritis (PsA), including patients with prior antitumour necrosis factor (TNF) therapy. We report efficacy and safety data from a 96-week data cut of RAPID-PsA. Methods RAPID-PsA was placebo-controlled to week 24, dose-blind to week 48 and open-label to week 216. We present efficacy data including American College of Rheumatology (ACR)/Psoriasis Area and Severity Index (PASI) responses, HAQ-DI, pain, minimal disease activity (MDA), modified total Sharp score (mTSS) and ACR responses in patients with/without prior anti-TNF exposure, in addition to safety data. Results Of 409 patients randomised, 273 received CZP from week 0. 54 (19.8%) CZP patients had prior anti-TNF exposure. Of patients randomised to CZP, 91% completed week 24, 87% week 48 and 80% week 96. ACR responses were maintained to week 96: 60% of patients achieved ACR20 at week 24, and 64% at week 96. Improvements were observed with both CZP dose regimens. ACR20 responses were similar in patients with (week 24: 59%; week 96: 63%) and without (week 24: 60%; week 96: 64%) prior anti-TNF exposure. Placebo patients switching to CZP displayed rapid clinical improvements, maintained to week 96. In patients with ≥3% baseline skin involvement (60.8% week 0 CZP patients), PASI responses were maintained to week 96. No progression of structural damage was observed over the 96-week period. In the Safety Set (n=393), adverse events occurred in 345 patients (87.8%) and serious adverse events in 67 (17.0%), including 6 fatal events. Conclusions CZP efficacy was maintained to week 96 with both dose regimens and in patients with/without prior anti-TNF exposure. The safety profile was in line with that previously reported from RAPID-PsA, with no new safety signals observed with increased exposure. Trial registration number NCT01087788.
Collapse
Affiliation(s)
- P Mease
- Swedish Medical Center and University of Washington , Seattle, Washington , USA
| | - A Deodhar
- Oregon Health & Science University , Portland, Oregon , USA
| | - R Fleischmann
- University of Texas SW Medical Center , Dallas, Texas , USA
| | | | - D Gladman
- Toronto Western Research Institute , Toronto , Canada
| | - P Leszczyński
- Poznan Medical University , Poznan , Poland ; Division of Rheumatology and Osteoporosis , Jozef Strus Hospital , Poznan , Poland
| | - P Vitek
- PV-MEDICAL, Revmavita Centre , Zlin , Czech Republic
| | - A Turkiewicz
- Rheumatology Associates Clinical Research Unit , Birmingham, Alabama , USA
| | - M Khraishi
- Department of Medicine , Memorial University of Newfoundland , St. John's , Canada
| | - O FitzGerald
- Department of Rheumatology , St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College , Dublin , Ireland
| | - R Landewé
- Academic Medical Center, Amsterdam and Atrium Medical Center , Heerlen , The Netherlands
| | | | | | - L Peterson
- UCB Pharma , Raleigh, North Carolina , USA
| | | |
Collapse
|
28
|
FitzGerald O, Fleischmann R, Hoepken B, Peterson L, Gladman D. THU0417 Improvements in Extra-Articular Manifestations of Psoriatic Arthritis Over 96 Weeks of Certolizumab Pegol Treatment. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
29
|
Khraishi M, Hoepken B, Davies O, Arledge T, Peterson L, Mease P. THU0427 Sustained Improvements in Skin Outcomes Following Certolizumab Pegol Treatment of Psoriatic Arthritis Patients with Prior Anti-TNF Exposure or Severe Skin Involvement at Baseline. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
30
|
Gladman D, Fleischmann R, Szegvari B, Peterson L, Mease PJ. Long-Term Maintenance of Improvements in Multiple Facets of Psoriatic Arthritis With Certolizumab Pegol: 96-Week Patient-Reported Outcome Results Of The Rapid-Psa Study. Value Health 2014; 17:A386. [PMID: 27200875 DOI: 10.1016/j.jval.2014.08.2646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- D Gladman
- Toronto Western Research Institute, Toronto, Ontario, ON, Canada
| | | | | | | | - P J Mease
- Swedish Medical Center and University of Washington, Seattle, WA, USA
| |
Collapse
|
31
|
Mease P, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, Peterson L, van der Heijde D. OP0077 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Psoriatic Arthritis with and without Prior Anti-Tumor Necrosis Factor Exposure: 96-Week Outcomes from the Rapid-Psa Trial. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
32
|
Smalyuk VA, Casey DT, Clark DS, Edwards MJ, Haan SW, Hamza A, Hoover DE, Hsing WW, Hurricane O, Kilkenny JD, Kroll J, Landen OL, Moore A, Nikroo A, Peterson L, Raman K, Remington BA, Robey HF, Weber SV, Widmann K. First measurements of hydrodynamic instability growth in indirectly driven implosions at ignition-relevant conditions on the National Ignition Facility. Phys Rev Lett 2014; 112:185003. [PMID: 24856703 DOI: 10.1103/physrevlett.112.185003] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/04/2013] [Indexed: 06/03/2023]
Abstract
Ignition experiments have shown an anomalous susceptibility to hydrodynamic instability growth. To help understand these results, the first hydrodynamic instability growth measurements in indirectly driven implosions on the National Ignition Facility were performed at ignition conditions with peak radiation temperatures up to ∼300 eV. Plastic capsules with two-dimensional preimposed, sinusoidal outer surface modulations of initial wavelengths of 240 (corresponding to a Legendre mode number of 30), 120 (mode 60), and 80 μm (mode 90) were imploded by using actual low-adiabat ignition laser pulses. The measured growth was in excellent agreement, validating 2D hydra simulations for the most dangerous modes in the acceleration phase. These results reinforce confidence in the predictive capability of calculations that are paramount to illuminating the path toward ignition.
Collapse
Affiliation(s)
- V A Smalyuk
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D T Casey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D S Clark
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M J Edwards
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S W Haan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Hamza
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D E Hoover
- General Atomics, San Diego, California 92121, USA
| | - W W Hsing
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O Hurricane
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J D Kilkenny
- General Atomics, San Diego, California 92121, USA
| | - J Kroll
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - O L Landen
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A Moore
- AWE Aldermaston, Reading, Berkshire RG7 4PR, United Kingdom
| | - A Nikroo
- General Atomics, San Diego, California 92121, USA
| | - L Peterson
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Raman
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B A Remington
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - H F Robey
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S V Weber
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Widmann
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
33
|
McElderry T, Waxman A, Gomberg-Maitland M, Burke M, Ross E, Bersohn M, Tarver J, Zwicke D, Feldman J, Chakinala M, Frantz R, Torres F, Li P, Morris M, Peterson L, Bourge R. Totally Implantable IV Treprostinil Therapy in Pulmonary Arterial Hypertension: Assessment of the Implantation Procedure. J Heart Lung Transplant 2014. [DOI: 10.1016/j.healun.2014.01.601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
34
|
Peterson L, Marbury T, Marier J, Laliberte K. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. J Clin Pharm Ther 2013; 38:518-23. [PMID: 24033615 DOI: 10.1111/jcpt.12094] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2013] [Accepted: 07/29/2013] [Indexed: 11/28/2022]
Abstract
WHAT IS KNOWN AND OBJECTIVE Treprostinil diolamine (oral treprostinil) is a prostacyclin analogue under evaluation for the treatment for pulmonary arterial hypertension (PAH). This study assessed the pharmacokinetics (PK) and safety of treprostinil following oral administration of a single sustained-release 1 mg dose in subjects with hepatic impairment. METHODS Four cohorts, including healthy volunteers, and subjects with mild, moderate and severe hepatic impairment were enrolled. Thirty subjects completed the study. Mean treprostinil clearance values (CL/F) decreased with the severity of hepatic impairment. The decrease in CL/F resulted in a marked increase in exposure levels of treprostinil. Relative to healthy subjects, mean area under the curve from time zero to 24 h after dosing interval (AUC0-24) values in subjects with mild, moderate and severe hepatic impairment increased by approximately 2·2-, 4·9- and 7·6-fold, respectively. The most frequent adverse events (AEs) exhibited in this study were similar to those seen with prostacyclin and its analogues and with AEs seen in other clinical studies with oral treprostinil (e.g. headache, diarrhoea and nausea). The overall incidence of all AEs and the specific events of headache and nausea increased with severity of hepatic impairment. WHAT IS NEW AND CONCLUSION Based on these results, dosage adjustments should be performed in subjects with hepatic impairment.
Collapse
Affiliation(s)
- L Peterson
- United Therapeutics Corporation, Research Triangle Park, NC, USA
| | | | | | | |
Collapse
|
35
|
Erdem E, Samant R, Malak SF, Culp WC, Brown A, Peterson L, Lensing S, Barlogie B. Vertebral augmentation in the treatment of pathologic compression fractures in 792 patients with multiple myeloma. Leukemia 2013; 27:2391-3. [PMID: 23728152 PMCID: PMC3865531 DOI: 10.1038/leu.2013.162] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- E Erdem
- Department of Radiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Minai OA, Parambil J, Dweik RA, Davila GH, Peterson L, Rollins KD, Chen H. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension. Respir Med 2012; 107:458-65. [PMID: 23266038 DOI: 10.1016/j.rmed.2012.10.023] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2011] [Revised: 09/26/2012] [Accepted: 10/30/2012] [Indexed: 11/24/2022]
Abstract
BACKGROUND Transition from intravenous (IV) epoprostenol to IV treprostinil in patients with pulmonary hypertension (PH) has traditionally been performed by gradually decreasing the epoprostenol dose while increasing the treprostinil dose. Preliminary data suggest that this transition can be performed more rapidly without the need for epoprostenol weaning. We conducted a single center, prospective clinical trial to assess the safety, efficacy, and treatment satisfaction of rapidly switching from epoprostenol to IV treprostinil. METHODS This study included patients with PH who had rapidly transitioned from epoprostenol to IV treprostinil. Data collected included clinical status, adverse events, PH symptoms, and previously validated measures of quality of life and treatment satisfaction. RESULTS Ten patients were enrolled in this study. Exercise capacity measured by mean 6-min walk distance was maintained from baseline throughout follow-up. Severity of disease as assessed by WHO functional class was maintained or improved for the majority of patients. Adverse events were minimal during the transition, and all patients remained on IV treprostinil throughout the follow-up period. A favorable impact on quality of life and treatment satisfaction measures was observed by eight weeks following the transition from epoprostenol to IV treprostinil. Specifically, time spent on drug preparation activities decreased by 39.5% with treprostinil compared to epoprostenol. CONCLUSIONS Rapidly switching from epoprostenol to IV treprostinil can be achieved without safety concerns, with minimal patient monitoring and without the need for extended hospitalization, while favorably impacting on patients' quality of life.
Collapse
Affiliation(s)
- O A Minai
- Department of Pulmonary, Allergy and Critical Care Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
| | | | | | | | | | | | | |
Collapse
|
37
|
|
38
|
Winckler JR, Peterson L, Hoffman R, Arnoldy R. Auroral x-rays, cosmic rays, and related phenomena during the storm of February 10-11, 1958. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/jz064i006p00597] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
39
|
Anderson KA, Arnoldy R, Hoffman R, Peterson L, Winckler JR. Observations of low-energy solar cosmic rays from the flare of 22 August 1958. ACTA ACUST UNITED AC 2012. [DOI: 10.1029/jz064i009p01133] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
40
|
Leentjens AFG, Rundell J, Rummans T, Shim JJ, Oldham R, Peterson L, Philbrick K, Soellner W, Wolcott D, Freudenreich O. Delirium: An evidence-based medicine (EBM) monograph for psychosomatic medicine practice, comissioned by the Academy of Psychosomatic Medicine (APM) and the European Association of Consultation Liaison Psychiatry and Psychosomatics (EACLPP). J Psychosom Res 2012; 73:149-52. [PMID: 22789420 DOI: 10.1016/j.jpsychores.2012.05.009] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2012] [Accepted: 05/25/2012] [Indexed: 11/26/2022]
Affiliation(s)
- A F G Leentjens
- Department of Psychiatry, Maastricht University Medical Centre, P.O. Box 5800, 6212 AZ Maastricht, The Netherlands.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Mitchell AC, Peterson L, Reardon CL, Reed SB, Culley DE, Romine MR, Geesey GG. Role of outer membrane c-type cytochromes MtrC and OmcA in Shewanella oneidensis MR-1 cell production, accumulation, and detachment during respiration on hematite. Geobiology 2012; 10:355-370. [PMID: 22360295 DOI: 10.1111/j.1472-4669.2012.00321.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The iron-reducing bacterium Shewanella oneidensis MR-1 has the capacity to contribute to iron cycling over the long term by respiring on crystalline iron oxides such as hematite when poorly crystalline phases are depleted. The ability of outer membrane cytochromes OmcA and MtrC of MR-1 to bind to and transfer electrons to hematite has led to the suggestion that they function as terminal reductases when this mineral is used as a respiratory substrate. Differences in their redox behavior and hematite-binding properties, however, indicate that they play different roles in the electron transfer reaction. Here, we investigated how these differences in cytochrome behavior with respect to hematite affected biofilm development when the mineral served as terminal electron acceptor (TEA). Upon attachment to hematite, cells of the wild-type (WT) strain as well as those of a ΔomcA mutant but not those of a ΔmtrC mutant replicated and accumulated on the mineral surface. The results indicate that MtrC but not OmcA is required for growth when this mineral serves as TEA. While an OmcA deficiency did not impede cell replication and accumulation on hematite prior to achievement of a maximum surface cell density comparable to that established by WT cells, OmcA was required for efficient electron transfer and cell attachment to hematite once maximum surface cell density was achieved. OmcA may therefore play a role in overcoming barriers to electron transfer and cell attachment to hematite imposed by reductive dissolution of the mineral surface from cell respiration associated with achievement of high surface cell densities.
Collapse
Affiliation(s)
- A C Mitchell
- Department of Microbiology and Center for Biofilm Engineering, Montana State University, Bozeman, MT, USA
| | | | | | | | | | | | | |
Collapse
|
42
|
Peterson L, Soliman A, Ruterbusch JJ, Smith N, Schwartz K. Comparison of exposures among Arab American and non-Hispanic White female thyroid cancer cases in metropolitan Detroit. J Immigr Minor Health 2012; 13:1033-40. [PMID: 21647624 DOI: 10.1007/s10903-011-9485-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Arab American (ArA) women may be at greater risk for thyroid cancer (TC) than White women. This case-case comparison explored differences in known and proposed risk factors of TC among ArA and non-Hispanic White (NHW) female TC cases in metropolitan Detroit. Cases of invasive TC identified from a population-based registry responded to a telephone survey regarding potential TC risk factors. Thirty ArA women (response rate 52%) and 70 NHW women (67%) participated. NHW women reported significantly more prior thyroid disease (TD), family history of TD, hormone use, cumulative years of hormone use, cigarette and alcohol consumption. In adjusted logistic regression analysis, ArA women had significantly higher odds of exposure to dental x-rays (OR = 3.48, CI 1.01-12.00) and medical radiation (OR = 13.58, CI 1.49-124.04) than NHW women. Risk factors for TC may differ among ArA women and their NHW counterparts.
Collapse
Affiliation(s)
- L Peterson
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
| | | | | | | | | |
Collapse
|
43
|
Soliera AR, Mariani SA, Audia A, Lidonnici MR, Addya S, Ferrari-Amorotti G, Cattelani S, Manzotti G, Fragliasso V, Peterson L, Perini G, Holyoake TL, Calabretta B. Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1. Leukemia 2012; 26:1555-63. [PMID: 22285998 DOI: 10.1038/leu.2012.19] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Expression of the transcription repressor Gfi-1 is required for the maintenance of murine hematopoietic stem cells. In human cells, ectopic expression of Gfi-1 inhibits and RNA interference-mediated Gfi-1 downregulation enhances proliferation and colony formation of p210BCR/ABL expressing cells. To investigate the molecular mechanisms that may explain the effects of perturbing Gfi-1 expression in human cells, Gfi-1-regulated genes were identified by microarray analysis in K562 cells expressing the tamoxifen-regulated Gfi-1-ER protein. STAT 5B and Mcl-1, two genes important for the proliferation and survival of hematopoietic stem cells, were identified as direct and functionally relevant Gfi-1 targets in p210BCR/ABL-transformed cells because: (i) their expression and promoter activity was repressed by Gfi-1 and (ii) when constitutively expressed blocked the proliferation and colony formation inhibitory effects of Gfi-1. Consistent with these findings, genetic or pharmacological inhibition of STAT 5 and/or Mcl-1 markedly suppressed proliferation and colony formation of K562 and CD34+ chronic myelogenous leukemia (CML) cells. Together, these studies suggest that the Gfi-1STAT 5B/Mcl-1 regulatory pathway identified here can be modulated to suppress the proliferation and survival of p210BCR/ABL-transformed cells including CD34+ CML cells.
Collapse
Affiliation(s)
- A R Soliera
- Department of Cancer Biology and Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Linden HM, Kurland BF, Livingston RB, Ellis GK, Gadi VK, Specht JM, Gralow J, Peterson L, Schubert EK, Xiaoyu S, Mankoff DA. Changes in FDG PET SUV and correlation with Ki-67 following 2 weeks of aromatase inhibitor therapy or trastuzumab in a pilot imaging study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e21077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Mankoff DA, Linden HM, Link J, Kurland BF, Schubert EK, Peterson L, Gadi VK, Specht JM, Shankar L, Eary JF. NCI-sponsored phase II study of [18f]fluoroestradiol (FES) as a marker of hormone sensitivity of metastatic breast cancer: Initial results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11104] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Jonasch E, Alvarez K, Peterson L, Tannir NM, Sircar K, Tamboli P, Monzon FA. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.339] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
339 Background: Antiangiogenic agents are used to treat metastatic clear cell renal cell carcinoma (ccRCC). Currently there are no biomarkers of therapeutic efficacy for these agents. Hypoxia inducible factor (HIF) alpha ratios have been linked to phenotypically distinct ccRCC subpopulations. The HIF1 alpha gene is located on chromosome 14q. In this study, the goal was to determine whether chromosomal imbalances identified with SNP arrays are linked to HIF ratios, and to clinical outcome. Methods: We obtained archival FFPE tumor specimens from 56 patients with mRCC treated with sorafenib or bevacizumab. DNA from the FFPE blocks was analyzed with Affymetrix 250K Nsp SNP microarrays. We identified the presence of genomic imbalances and loss of heterozygosity (LOH) to obtain virtual karyotypes. We then evaluated candidate genes in gain/lost chromosomal regions by qPCR and immunohistochemistry (IHC) in the bevacizumab treated specimens. Results: In the bevacizumab cohort, HIF1-alpha containing14q loss showed a significant association with worse response to treatment (CR/ PR vs. SD/PD, Fisher exact test, p = 0.0473). In addition, HIF1A mRNA expression was significantly reduced in all samples with 14q loss and was associated with PFS (HR = 2.29, 95% CI = 1.01-5.16, p = 0.045). HIF-1alpha protein expression was also reduced in samples with 14q loss. Conclusions: Chromosomal imbalances are associated with outcomes in ccRCC patients treated with antiangiogenic agents, and can lead to changes in gene expression. Low HIF1A expression was strongly correlated with shorter PFS. We hypothesize that loss of 14q could lead to an imbalance in HIF-1alpha/HIF-2alpha activity, leading to increased HIF-2alpha and enhanced c-Myc expression, which improves tumor cell viability and engenders resistance to cellular stress induced by antiangiogenic therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- E. Jonasch
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| | - K. Alvarez
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| | - L. Peterson
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| | - N. M. Tannir
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| | - K. Sircar
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| | - P. Tamboli
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| | - F. A. Monzon
- University of Texas M. D. Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX
| |
Collapse
|
47
|
|
48
|
Affiliation(s)
- L Peterson
- Department of Psychology University of Utah Salt Lake City, Utah 84112
| | | |
Collapse
|
49
|
Monzon FA, Alvarez K, Amato RJ, Peterson L, Shen SS, Hernandez-McClain J, Sircar K, Tamboli P, Tannir NM, Jonasch E. Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e15012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Vasiliadis H, Salanti G, Georgoulis A, Lindahl A, Peterson L. WITHDRAWN: Assessment of clinical outcomes 10-20 years after autologous chondrocyte implantation. Osteoarthritis Cartilage 2010:S1063-4584(10)00104-4. [PMID: 20450980 DOI: 10.1016/j.joca.2010.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 03/31/2010] [Accepted: 04/07/2010] [Indexed: 02/02/2023]
Affiliation(s)
- H Vasiliadis
- Molecular Cell Biology and Regenerative Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden; Orthopaedic Sports Medicine Center, Department of Orthopaedics, University of Ioannina, Greece
| | | | | | | | | |
Collapse
|